Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: PIPAC Oxaliplatin and Nivolumab in Gastric Cancer
NCT03172416Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Apr 2017
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 1, open-label trial of oxaliplatin and nivolumab in gastric cancer (GC) and peritoneal carcinomatosis (PC) (2 cohorts), sponsored by National University Hospital. Primary endpoints: Safety Profile of PIPAC with oxaliplatin, Tolerability of PIPAC with oxaliplatin and 3 more. Started Apr 2017; status: active, not recruiting.
02
Drugs
oxaliplatinnivolumab
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03172416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172416.